We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at WallStreetSectors.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.
- Recent INSM Stock Price: $20.85
- Yearly Gain for INSM stock: -9.63%
- Market Cap for INSM stock: $2.75B
- P/E Ratio for INSM stock: -5.577
Will INSM's stock price go up? Is there an accurate INSM stock forecast available?
TipRanks.com reports that Insmed currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $34.80. The target pricing ranges from a high INSM forecast of $39.00 down to a low forecast of $28.00. Insmed (INSM)’s last closing stock price was $20.85 which would put the average price target at 66.91% upside.
In addition, TradingView issued a Buy rating for INSM stock over the next month, Barchart.com has a hold rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on INSM stock.
Other analysts covering INSM include:
- Stephen Willey of Stifel Nicolaus issued a Buy rating with the price target of $ 34 on 4 days ago
- Leon Wang of Barclays issued a Buy rating with the price target of $ 35 on 1 month ago
- Andrea Tan of Goldman Sachs issued a Buy rating with the price target of $ 39 on 1 month ago
- Jessica Fye of J.P. Morgan issued a Buy rating with the price target of $ 38 on 2 months ago
If you are wondering if INSM is a good stock to buy, here are 3rd party ratings for INSM stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: hold
- Zacks.com: Hold, Top 36% (91 out of 251)
What is the sentiment on the street regarding Insmed? (Current ratings compiled by TipRanks.com)
- News Sentiment for INSM stock: Very Bullish
- Blogger Consensus for INSM stock: ―
- Media Buzz for INSM stock: High
- Insider Signal for INSM stock: Negative
- Investor Sentiment for INSM stock: ―
- Hedge Fund signal for INSM stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on INSM stock including scouring the social networks like INSM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for INSM stock chart >>
Summary: Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.
- Recent APLS Stock Price: $68.81
- Yearly Gain for APLS stock: 57.43%
- Market Cap for APLS stock: $6.47B
- P/E Ratio for APLS stock: -10.732
Will APLS's stock price go up? Is there an accurate APLS stock forecast available?
TipRanks.com reports that Apellis Pharmaceuticals currently has 12 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $83.92. The target pricing ranges from a high APLS forecast of $139.00 down to a low forecast of $50.00. Apellis Pharmaceuticals (APLS)’s last closing stock price was $68.81 which would put the average price target at 21.96% upside.
In addition, TradingView issued a n/a (possibly response change) rating for APLS stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on APLS stock.
Other analysts covering APLS include:
- Laura Chico of Wedbush issued a Hold rating with the price target of $ 51 on 1 day ago
- Yigal Nochomovitz of Citigroup issued a Buy rating with the price target of $ 91 on 2 days ago
- Colleen M. Kusy of Robert W. Baird issued a Buy rating with the price target of $ 105 on 2 days ago
- Annabel Samimy of Stifel Nicolaus issued a Buy rating with the price target of $ 75 on 2 days ago
If you are wondering if APLS is a good stock to buy, here are 3rd party ratings for APLS stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 36% (91 out of 251)
What is the sentiment on the street regarding Apellis Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for APLS stock: Very Bullish
- Blogger Consensus for APLS stock: Bullish
- Media Buzz for APLS stock: Very High
- Insider Signal for APLS stock: Positive
- Investor Sentiment for APLS stock: Very Positive
- Hedge Fund signal for APLS stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on APLS stock including scouring the social networks like APLS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for APLS stock chart >>
Summary: 4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.
- Recent FDMT Stock Price: $20.70
- Yearly Gain for FDMT stock: 49.12%
- Market Cap for FDMT stock: $653.03M
- P/E Ratio for FDMT stock: -6.086
Will FDMT's stock price go up? Is there an accurate FDMT stock forecast available?
TipRanks.com reports that 4D Molecular Therapeutics currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $32.00. The target pricing ranges from a high FDMT forecast of $50.00 down to a low forecast of $14.00. 4D Molecular Therapeutics (FDMT)’s last closing stock price was $20.70 which would put the average price target at 54.59% upside.
In addition, TradingView issued a Buy rating for FDMT stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on FDMT stock.
Other analysts covering FDMT include:
- Tazeen Ahmad of Bank of America Securities issued a Buy rating with the price target of $ 28 on 10 hours ago
- Kostas Biliouris of BMO Capital issued a Buy rating with the price target of $ 50 on 10 hours ago
- Mani Foroohar of SVB Securities issued a Hold rating with the price target of $ 14 on 2 weeks ago
- Salveen Richter of Goldman Sachs issued a Buy rating with the price target of $ 68 on 3 months ago
If you are wondering if FDMT is a good stock to buy, here are 3rd party ratings for FDMT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Top 40% (100 out of 251)
What is the sentiment on the street regarding 4D Molecular Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for FDMT stock: Neutral
- Blogger Consensus for FDMT stock: Bullish
- Media Buzz for FDMT stock: Very Low
- Insider Signal for FDMT stock: ―
- Investor Sentiment for FDMT stock: Very Positive
- Hedge Fund signal for FDMT stock: Neutral
The stock market is extremely volatile, and you need to do your own research on FDMT stock including scouring the social networks like FDMT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for FDMT stock chart >>
Summary: Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries. Seagen has an agreement with Takeda Pharmaceutical Company Ltd. for the further development and commercialization of Adcetris. Seagen retains all rights to sell Adcetris in the U.S. and Canada, while Takeda has commercial rights to the drug in the rest of the world. The FDA granted approvals to Seagen's several drugs named Padcev, for treating advanced/metastatic urothelial cancer; Tukysa and Tivdak for treating adult patients with locally advanced/metastatic HER2-positive breast cancer and for the treatment of recurrent/metastatic cervical cancer in adult patients respectively. The company also has license agreements with partners like Merck, Roche, GlaxoSmithKline, Astellas, AbbVie, Bristol-Myers and Genmab.
- Recent SGEN Stock Price: $161.71
- Yearly Gain for SGEN stock: 34.43%
- Market Cap for SGEN stock: $29.25B
- P/E Ratio for SGEN stock: -48.662
Will SGEN's stock price go up? Is there an accurate SGEN stock forecast available?
TipRanks.com reports that Seagen currently has 18 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $165.47. The target pricing ranges from a high SGEN forecast of $180.00 down to a low forecast of $141.00. Seagen (SGEN)’s last closing stock price was $161.71 which would put the average price target at 2.98% upside.
In addition, TradingView issued a Buy rating for SGEN stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SGEN stock.
Other analysts covering SGEN include:
- Jay Olson of Oppenheimer issued a Buy rating with the price target of $ 180 on 2 days ago
- Asthika Goonewardene of Truist Financial issued a Hold rating with the price target of $ 152 on 6 days ago
- Reni Benjamin of JMP Securities issued a Buy rating with the price target of $ 168 on 6 days ago
- Gregory Renza of RBC Capital issued a Buy rating with the price target of $ 155 on 1 week ago
If you are wondering if SGEN is a good stock to buy, here are 3rd party ratings for SGEN stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 36% (91 out of 251)
What is the sentiment on the street regarding Seagen? (Current ratings compiled by TipRanks.com)
- News Sentiment for SGEN stock: Very Bullish
- Blogger Consensus for SGEN stock: Bullish
- Media Buzz for SGEN stock: Medium
- Insider Signal for SGEN stock: Positive
- Investor Sentiment for SGEN stock: Very Positive
- Hedge Fund signal for SGEN stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on SGEN stock including scouring the social networks like SGEN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SGEN stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, WallStreetSectors.com
WallStreetSectors.com keeps investors investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to WallStreetSectors.com.
==============================================================================
